Search research articles
Contact Us
Filters
Showing results (321-330 of 524) with videos related to
Page
of 53
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2017
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i>-Mutant Non-Small Cell Lung Cancer
Kathryn C Arbour, Emmett Jordan, Hyunjae Ryan Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2008
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer
Gregory J Riely, Naiyer A Rizvi, Mark G Kris, et al.
Biorxiv : the Preprint Server for Biology
|
July 14, 2025
Complementary modes of resistance to <i>EGFR</i> TKI in lung adenocarcinoma through MAPK activation and cellular plasticity
Matthew Zatzman, Alvaro Quintanal-Villalonga, Sohrab Salehi, et al.
JCO Precision Oncology
|
April 23, 2019
Harnessing Clinical Sequencing Data for Survival Stratification of Patients with Metastatic Lung Adenocarcinomas
Ronglai Shen, Axel Martin, Ai Ni, et al.
Bioconjugate Chemistry
|
April 9, 2021
Synthesis and Comparative <i>In Vivo</i> Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET
Sai Kiran Sharma, Pierre Adumeau, Outi Keinänen, et al.
JCO Precision Oncology
|
September 14, 2020
CNS Metastases in Patients With <i>MET</i> Exon 14-Altered Lung Cancers and Outcomes With Crizotinib
Michael Offin, Jia Luo, Robin Guo, et al.
JCO Precision Oncology
|
September 11, 2024
Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and <i>MDM2</i> Amplification
Arielle Elkrief, Igor Odintsov, Roger S Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2011
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors
Patricia M LoRusso, Charles M Rudin, Josina C Reddy, et al.
Biorxiv : the Preprint Server for Biology
|
October 9, 2023
Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma
Zhuxuan Li, Xueqian Zhuang, Chun-Hao Pan, et al.
The Journal of Clinical Investigation
|
November 21, 2018
Peptide-based PET quantifies target engagement of PD-L1 therapeutics
Dhiraj Kumar, Ala Lisok, Elyes Dahmane, et al.
Page
of 53
Search research articles
Search
Showing results (321-330 of 524) with videos related to
Sort By:
Page
of 53
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2017
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i>-Mutant Non-Small Cell Lung Cancer
Kathryn C Arbour, Emmett Jordan, Hyunjae Ryan Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2008
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer
Gregory J Riely, Naiyer A Rizvi, Mark G Kris, et al.
Biorxiv : the Preprint Server for Biology
|
July 14, 2025
Complementary modes of resistance to <i>EGFR</i> TKI in lung adenocarcinoma through MAPK activation and cellular plasticity
Matthew Zatzman, Alvaro Quintanal-Villalonga, Sohrab Salehi, et al.
JCO Precision Oncology
|
April 23, 2019
Harnessing Clinical Sequencing Data for Survival Stratification of Patients with Metastatic Lung Adenocarcinomas
Ronglai Shen, Axel Martin, Ai Ni, et al.
Bioconjugate Chemistry
|
April 9, 2021
Synthesis and Comparative <i>In Vivo</i> Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET
Sai Kiran Sharma, Pierre Adumeau, Outi Keinänen, et al.
JCO Precision Oncology
|
September 14, 2020
CNS Metastases in Patients With <i>MET</i> Exon 14-Altered Lung Cancers and Outcomes With Crizotinib
Michael Offin, Jia Luo, Robin Guo, et al.
JCO Precision Oncology
|
September 11, 2024
Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and <i>MDM2</i> Amplification
Arielle Elkrief, Igor Odintsov, Roger S Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2011
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors
Patricia M LoRusso, Charles M Rudin, Josina C Reddy, et al.
Biorxiv : the Preprint Server for Biology
|
October 9, 2023
Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma
Zhuxuan Li, Xueqian Zhuang, Chun-Hao Pan, et al.
The Journal of Clinical Investigation
|
November 21, 2018
Peptide-based PET quantifies target engagement of PD-L1 therapeutics
Dhiraj Kumar, Ala Lisok, Elyes Dahmane, et al.
Page
of 53